Leukemia Clinical Trials in Los Angeles

Showing 481-500 of 1,205 trials

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

NCT04101357

This first-in-human (FIH) trial aimed to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide. BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune checkpoint inhibitors.

Solid TumorExtensive-stage Small Cell Lung Cancer

BioNTech SE54 participantsStarted Jun 2020

Los Angeles, California, United States • Chicago, Illinois, United States • Greenville, South Carolina, United States +9 more locations

RECRUITINGPhase 1< 1 mile

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

NCT05190471

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory

Bio-Path Holdings, Inc.48 participantsStarted Aug 2022

La Jolla, California, United States • Los Angeles, California, United States • New York, New York, United States +1 more locations

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Leukemia Trials in Other Cities

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Bright Ideas - CIN Feasibility Study

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Avelumab in First-line NSCLC (JAVELIN Lung 100)

A Study of SGN-ALPV in Advanced Solid Tumors

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Other Conditions in Los Angeles